Alzheimer's

Question 1

Cholinesterase Inhibitor

• Mild, moderate, or severe AD
• Reversible inhibition of AChE—but is more selective for the form of AChE found in the brain than that found in the periphery
• Highly protein bound and has a prolonged plasma half-life (about 60 hours)
• Can cause bradycardia, fainting, falls, and fall-related fractures

Answer 1

Donezepil

Question 3

Cholinesterase Inhibitor

• Approved for AD and for dementia of Parkinson disease
• Irreversible inhibition of AChE
• With oral dosing, the most common cholinergic effects are nausea, vomiting, diarrhea, abdominal pain, tremors, and anorexia. Weight loss (7% of initial weight) occurs in 18% of male to 26% of female patients
  *can cause bradycardia, fainting, falls, and fall-related fractures

Answer 3

Rivastigmine

Question 4

Cholinesterase Inhibitor

• Reversible cholinesterase inhibitor
• Most common adverse effects are nausea, vomiting, diarrhea, anorexia, and weight loss

Question 5

N-Methyl-D-Aspartate Receptor Antagonist

• indicated only for moderate or severe AD
• Modulates the effects of glutamate (the major excitatory transmitter in the central nervous system) at NMDA receptors, which are believed to play a critical role in learning and memory
• The NMDA receptor—a transmembrane protein with a central channel—regulates calcium entry into neurons. The binding of glutamate to the receptor promotes calcium influx

Blocks calcium influx when extracellular glutamate is low but permits calcium influx when extracellular glutamate is high

Answer 5

Memantine